Erasca, Inc. Stock Price, News & Analysis

Erasca, Inc. (Nasdaq: ERAS) has been added to the NASDAQ Biotech Index, effective December 20, 2021. This index tracks biotech and pharmaceutical companies listed on the Nasdaq, and membership requires meeting specific criteria, including market capitalization and trading volume. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers and is backed by experts in precision oncology. This inclusion indicates recognition of the company's growth and stability in the biotechnology sector.

Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.

Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.

Erasca, Inc. (Nasdaq: ERAS) reported strong execution in its recent financial results for Q3 2021, highlighting the initiation of two clinical trials for ERAS-007 in lung and gastrointestinal cancers. The company maintained a robust cash position of $487 million, bolstered by a $345 million IPO. Notably, it was named one of Fierce Biotech's "Fierce 15" innovative companies. However, the firm reported a net loss of $46.1 million for the quarter, influenced by significant R&D and G&A expenses, including a $17.5 million donation to the Erasca Foundation.

Erasca, Inc. (Nasdaq: ERAS) presented promising preclinical data for ERAS-801, a new EGFR inhibitor with significantly enhanced CNS penetration, at the AACR Conference. ERAS-801 shows a CNS penetration rate four times higher than existing EGFR inhibitors, demonstrating potent efficacy in over 90% of tested EGFR-mutant glioblastoma models. The company plans to submit an IND for refractory glioblastoma in Q1 2022. These advancements highlight ERAS-801's potential to improve outcomes for patients suffering from this aggressive cancer type.

Erasca, Inc. (Nasdaq: ERAS) announced the dosing of the first patient in the HERKULES-3 trial, a Phase 1b/2 clinical study evaluating ERAS-007, an ERK1/2 inhibitor, in combination with various agents for treating colorectal cancer (CRC). The trial aims to address mutations in BRAF, KRAS, and NRAS, impacting over half of CRC patients. Current therapies show limited effectiveness, with many patients experiencing rapid disease progression. HERKULES-3 will explore the safety and effectiveness of these combinations, potentially leading to significant advancements in CRC treatment.

ERAS-007, a leading ERK1/2 inhibitor, has entered Phase 1b/2 HERKULES-2 trial, focusing on advanced non-small cell lung cancer (NSCLC). Erasca, Inc. has initiated patient dosing to evaluate ERAS-007's effectiveness in combination with osimertinib. This trial aims to address unmet needs, especially for patients resistant to current therapies. The broad applicability of ERAS-007 was reinforced by recent preclinical findings showing strong anti-tumor activity, particularly in tumors with specific mutations. Future expansions will explore additional combinations across various cancer types.

Erasca, Inc. (Nasdaq: ERAS) announced a clinical trial collaboration with Pfizer to evaluate ERAS-007, an ERK1/2 inhibitor, in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer. The HERKULES-3 Phase 1b/2 trial is set to start in H2 2021. The collaboration aims to address the challenge of resistance observed in existing treatments. With about 1.8 million CRC cases globally and 10% related to BRAF V600E mutations, this trial could significantly impact patient outcomes.

San Diego-based Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event features a fireside chat with CEO Jonathan E. Lim and CFO David M. Chacko on September 10, 2021, at 4:15 PM ET. The live webcast can be accessed on the company’s website, with an archived replay available for 30 days post-event. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer through innovative treatments.